Manufacturing

Articles

The investment will include new manufacturing lines and increased automation to deliver additional manufacturing capacity.

Cytiva Invests $500 Million Over 5 years to Expand Global Capacity

The European Medicines Agency recently approved two European Novartis sites in France and Switzerland for the commercial manufacturing of chimeric antigen receptor T-cell cell therapies.

Novartis Gets EMA Approval for Two European Commercial CAR-T Manufacturing Sites

Feliza Mirasol is the science editor for 

The early success seen on the market for approved cell and gene therapies poses both technical and manufacturing challenges for pipeline candidates on the road to commercialization.

Commercialization Poses Challenges for Cell and Gene Therapies

Francesca McBride is director of Regulatory Compliance at Jacobs,  Francesca.McBride@Jacobs.com.

Manufacturers must address scale-out challenges of autologous cell therapy for commercial manufacturing.

Overcoming Operational and Regulatory Challenges in Autologous Cell-Therapy Facilities

The site can now support customized product and bioprocess development and custom cell and gene therapy reagent manufacturing. 

Avantor Expands its New Jersey Innovation Center

The company will invest $75 million into its Canton, MA, facility to expand its viral vector, gene therapy, and contract development and manufacturing capabilities.

Emergent to Invest $75 Million to Expand Manufacturing Capabilities

The VIA Capsule from Cytiva is a liquid nitrogen-free cryogenic shipment system designed to transport cell therapies.

Cryogenic Capsule for Shipment of Cellular Therapies

Ori Biotech is partnering with manufacturers and materials suppliers to develop an automated system for cell and gene therapy manufacturing. 

Ori Biotech and CellGenix Collaborate on Closed-system, Cell and Gene Therapy Manufacturing

Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma entered into long-term development and manufacturing services agreements for the clinical and commercial supply of multiple bluebird bio therapies.

HCATS, apceth Biopharma Form Strategic Manufacturing Agreements with bluebird bio

The center will be located at NJIT’s Life Sciences and Engineering center and will feature two good manufacturing practices suites that are expected to be completed and operational during the summer of 2020. 

Manufacturing, Cell Therapies